Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 15/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.44 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4374421 | 0.79 | AR (0.55) | SLC22A12SCN9AEZH2 | |
| SCHEMBL1094054 | 0.76 | SCN9A (0.71) | SCN9A | |
| SCHEMBL31729379 | 0.76 | TRPV4 (0.48) | SLC22A12 | |
| SCHEMBL1156122 | 0.76 | TRPV4 (0.48) | SLC22A12 | |
| SCHEMBL18603934 | 0.76 | POLB (0.53) | SLC22A12EZH2 | |
| SCHEMBL30872202 | 0.76 | POLB (0.53) | SLC22A12EZH2 | |
| SCHEMBL14662041 | 0.75 | EZH2 (0.45) | SLC22A12SCN9AEZH2 | |
| SCHEMBL319459 | 0.73 | ACLY (0.47) | SLC22A12 | |
| SCHEMBL7054403 | 0.72 | GAA (0.64) | SLC22A12 | |
| SCHEMBL1941288 | 0.70 | EPAS1 (0.41) | SLC22A12SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140206865-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20130144056-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| EP-1511488-B1 | HUMAN ADAM-10 INHIBITORS | SYMPHONY EVOLUTION INC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20120270884-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2482817-A1 | METHODS OF TREATING ANEURYSMAL DILATATION, BLOOD VESSEL WALL WEAKNESS AND SPECIFICALLY ABDOMINAL AORTIC AND THORACIC ANEURYSM USING MATRIX METALLOPROTEASE-2 INHIBITORS | Symphony Evolution, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2436676-A1 | Human adam-10 inhibitors | Symphony Evolution, Inc. (US) | 2012-04-04 | — | — | EP | disclosed |
| US-20120071653-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2428509-A1 | Human adam-10 inhibitors | Symphony Evolution, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7989661-B2 | Human ADAM-10 inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110082114-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041545-A1 | METHODS OF TREATING ANEURYSMAL DILATATION, BLOOD VESSEL WALL WEAKNESS AND SPECIFICALLY ABDOMINAL AORTIC AND THORACIC ANEURYSM USING MATRIX METALLOPROTEASE-2 INHIBITORS | SYMPHONY EVOLUTION, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20100105953-A1 | Human Adam-10 Inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-7629341-B2 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | SYMPHONY EVOLUTION, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1511488-A4 | HUMAN ADAM-10 INHIBITORS | EXELIXIS INC (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20060199820-A1 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | SYMPHONY EVOLUTION, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1511488-A2 | HUMAN ADAM-10 INHIBITORS | Exelixis, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003106381-A2 | HUMAN ADAM-10 INHIBITORS | EXELIXIS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270884-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | ADAM10, ADAM17, ADAM12 | SLC22A12 1359/4885SCN9A 3843/4885EZH2 4844/4885 |
| US-20060199820-A1 | e.g. N1-hydroxy-N2-[(4-phenoxyphenyl)sulfonyl]-D-argininamide; metallopeptidase inhibitor; antiinflammation, anticarcinogenic, antidiabetic agent; angiogenesis inhibitor; atherosclerosis, stroke, ulcer, infertility, scleroderma, endometriosis, mesothelioma | ADAM10, MMP20, MMP10 | SLC22A12 2618/4885SCN9A 667/4885EZH2 899/4885 |
| US-20120071653-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | SLC22A12 663/4885SCN9A 1349/4885EZH2 3415/4885 |
| US-20100105953-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | SLC22A12 663/4885SCN9A 1349/4885EZH2 3415/4885 |
| US-20110082114-A1 | Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors | ADAM10, ADAM17, ADAM12 | SLC22A12 928/4885SCN9A 3620/4885EZH2 4827/4885 |
| US-20140206865-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | SLC22A12 663/4885SCN9A 1349/4885EZH2 3415/4885 |
| US-20130144056-A1 | Human Adam-10 Inhibitors | ADAM10, MMP20, ADAM9 | SLC22A12 663/4885SCN9A 1349/4885EZH2 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.